Allogene Therapeutics (ALLO) News Today

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 4.4%

Allogene Therapeutics (NASDAQ:ALLO) Sees Unusually-High Trading Volume

Susquehanna Fundamental Investments LLC bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 286,408 shares of the company's stock, valued at approximately $1,280,000. Susqueh

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 43,280,000 shares, an increase of 6.7% from the May 31st total of 40,570,000 shares. Approximately 31.7% of the company's shares are short sold. Based on an average daily trading volume, of 2,530,000 shares, the short-interest ratio is currently 17.1 days.

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 4.6%

Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Up to $2.23

Allogene Therapeutics (NASDAQ:ALLO) Trading 9.4% Higher

Caxton Associates LP grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 61.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 775,093 shares of the company's stock after acq

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at Zacks Research increased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a report issued on Monday, June 3rd. Zacks Research analyst S. Ganoria now expects that the company will post earnings per sha

Affinity Asset Advisors LLC acquired a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 400,000 shares of the company's stock,

BNP Paribas Financial Markets trimmed its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 78.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 123,518 shares of the company's stock after selling 446,437 shares during the period. B

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) Director Franz B. Humer sold 11,200 shares of Allogene Therapeutics stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $2.34, for a total transaction of $26,208.00. Following the sale, the director now owns 255,253 shares of the company's stock, valued at $597,292.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 36,430,000 shares, an increase of 7.6% from the April 30th total of 33,870,000 shares. Based on an average trading volume of 2,320,000 shares, the days-to-cover ratio is presently 15.7 days. Approximately 30.1% of the shares of the company are sold short.

Piper Sandler initiated coverage on Allogene Therapeutics in a report on Friday. They issued an "overweight" rating and a $11.00 target price for the company.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) Director Arie Belldegrun bought 1,724,137 shares of the company's stock in a transaction on Thursday, May 16th. The shares were acquired at an average price of $2.90 per share, for a total transaction of $4,999,997.30. Following the transaction, the director now directly owns 1,724,137 shares in the company, valued at approximately $4,999,997.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Oppenheimer reduced their price target on Allogene Therapeutics from $14.00 to $13.00 and set an "outperform" rating for the company in a research report on Tuesday.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Allogene Therapeutics in a report released on Thursday, May 16th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.3

HC Wainwright dropped their price objective on Allogene Therapeutics from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at William Blair cut their Q2 2024 earnings per share (EPS) estimates for Allogene Therapeutics in a report issued on Tuesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will post earnings

Truist Financial reaffirmed a "buy" rating and issued a $17.00 target price on shares of Allogene Therapeutics in a report on Wednesday.

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 9.5% Following Analyst Upgrade

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at William Blair issued their FY2025 earnings estimates for shares of Allogene Therapeutics in a note issued to investors on Tuesday, May 14th. William Blair analyst S. Corwin anticipates that the company will post earnings

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) issued its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative return on equity of 53.76%. Allogene Therapeutics's revenue was down 26.7% on a year-over-year basis. During the same period last year, the business posted ($0.68) EPS.

Stifel Nicolaus increased their target price on Allogene Therapeutics from $4.40 to $4.60 and gave the company a "hold" rating in a research note on Tuesday.